当前位置: 首页 >> 检索结果
2503. A historic moment for open science: the Yale University Open Data Access project and medtronic.
作者: Harlan M Krumholz.;Joseph S Ross.;Cary P Gross.;Ezekiel J Emanuel.;Beth Hodshon.;Jessica D Ritchie.;Jeffrey B Low.;Richard Lehman.
来源: Ann Intern Med. 2013年158卷12期910-1页 2505. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis.
作者: Rongwei Fu.;Shelley Selph.;Marian McDonagh.;Kimberly Peterson.;Arpita Tiwari.;Roger Chou.;Mark Helfand.
来源: Ann Intern Med. 2013年158卷12期890-902页
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is used as a bone graft substitute in spinal fusion, which unites (fuses) bones in the spine. The accuracy and completeness of journal publications of industry-sponsored trials on the effectiveness and harms of rhBMP-2 has been called into question.
2506. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data.
作者: Mark C Simmonds.;Jennifer V E Brown.;Morag K Heirs.;Julian P T Higgins.;Richard J Mannion.;Mark A Rodgers.;Lesley A Stewart.
来源: Ann Intern Med. 2013年158卷12期877-89页
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is widely used to promote fusion in spinal surgery, but its safety has been questioned.
2507. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study.
作者: Amit M Patel.;Salimah Shariff.;David G Bailey.;David N Juurlink.;Sonja Gandhi.;Muhammad Mamdani.;Tara Gomes.;Jamie Fleet.;Y Joseph Hwang.;Amit X Garg.
来源: Ann Intern Med. 2013年158卷12期869-76页
Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.
2508. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
作者: Kenneth W Mahaffey.;Daniel Wojdyla.;Graeme J Hankey.;Harvey D White.;Christopher C Nessel.;Jonathan P Piccini.;Manesh R Patel.;Scott D Berkowitz.;Richard C Becker.;Jonathan L Halperin.;Daniel E Singer.;Robert M Califf.;Keith A A Fox.;Günter Breithardt.;Werner Hacke.
来源: Ann Intern Med. 2013年158卷12期861-8页
In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation.
2509. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
作者: Julia H Hayes.;Daniel A Ollendorf.;Steven D Pearson.;Michael J Barry.;Philip W Kantoff.;Pablo A Lee.;Pamela M McMahon.
来源: Ann Intern Med. 2013年158卷12期853-60页
Observation is underutilized among men with localized, low-risk prostate cancer.
2513. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
作者: Walid F Gellad.;Julie M Donohue.;Xinhua Zhao.;Maria K Mor.;Carolyn T Thorpe.;Jeremy Smith.;Chester B Good.;Michael J Fine.;Nancy E Morden.
来源: Ann Intern Med. 2013年159卷2期105-14页
Medicare Part D and the U.S. Department of Veterans Affairs (VA) use different approaches to manage prescription drug benefits, with implications for spending. Medicare relies on private plans with distinct formularies, whereas the VA administers its own benefit using a national formulary.
|